RISPERIDONE BNM, RIXADONE (Boucher & Muir Pty Ltd)

RISPERIDONE BNM, RIXADONE (oral liquid solution) are indicated for:

• the treatment of schizophrenia and related psychoses
• the short-term treatment of acute mania associated with Bipolar 1 Disorder
• the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the Alzheimers type
• the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent
• the treatment of behavioural disorders associated with autism in children and adolescents